Copyright
©The Author(s) 2016.
World J Hepatol. Jan 18, 2016; 8(2): 92-106
Published online Jan 18, 2016. doi: 10.4254/wjh.v8.i2.92
Published online Jan 18, 2016. doi: 10.4254/wjh.v8.i2.92
NS3/4A PIs | First-generation protease inhibitors |
Telaprevir | |
Boceprevir | |
Second-generation protease inhibitors | |
Simeprevir | |
Faldaprevir | |
Paritaprevir | |
Ritonavir | |
NS5B NPIs | Sofosbuvir |
NS5B NNPIs | Dasabuvir |
NS5A inhibitors | Daclatasvir |
Ledipasvir | |
Ombitasvir |
- Citation: Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri MI, Scuderi L, Malaguarnera G, Bertino N, Rapisarda V, Di Carlo I, Toro A, Salomone F, Malaguarnera M, Bertino E, Malaguarnera M. Chronic hepatitis C: This and the new era of treatment. World J Hepatol 2016; 8(2): 92-106
- URL: https://www.wjgnet.com/1948-5182/full/v8/i2/92.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i2.92